In that analysis FDA discusses the need for the rule, the benefits anticipated from the implementation of the rule, and a summary of the impacts of the final rule.
The rule may be unpopular among drug manufacturers but the benefits outweigh those concerns.
mnli hypothesis: The rule may be unpopular among drug manufacturers but the benefits outweigh those concerns. premise: In that analysis FDA discusses the need for the rule, the benefits anticipated from the implementation of the rule, and a summary of the impacts of the final rule.